Todo DSpace

Listar por tema "proprotein convertase 9"

Mostrando ítems 1-6 de 6

    • Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018 

      Ahmed N., Audebert H., Turc G., Cordonnier C., Christensen H., Sacco S., Sandset E.C., Ntaios G., Charidimou A., Toni D., Pristipino C., Köhrmann M., Kuramatsu J.B., Thomalla G., Mikulik R., Ford G.A., Martí-Fàbregas J., Fischer U., Thoren M., Lundström E., Rinkel G.J.E., Worp H.B.V.D., Matusevicius M., Tsivgoulis G., Milionis H., Rubiera M., Hart R., Moreira T., Lantz M., Sjöstrand C., Andersen G., Schellinger P., Kostulas K., Sunnerhagen K.S., Keselman B., Korompoki E., Purrucker J., Khatri P., Whiteley W., Berge E., Mazya M., Dippel D.W.J., Mustanoja S., Rasmussen M., Söderqvist Å.K., Escudero-Martínez I., Steiner T. (2019)
      The purpose of the European Stroke Organisation–Karolinska Stroke Update Conference is to provide updates on recent stroke therapy research and to give an opportunity for the participants to discuss how these results may ...

    • Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 

      Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)
      Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ...

    • Lipid-lowering treatment in peripheral artery disease 

      Katsiki N., Giannoukas A.D., Athyros V.G., Mikhailidis D.P. (2018)
      Peripheral artery disease (PAD) is characterized by increased cardiovascular (CV) risk, limb morbidity and all-cause mortality. According to the current guidelines (2016) of the American Heart Association/American College ...

    • Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke 

      Ntaios G., Milionis H. (2019)
      Background: Low-density lipoprotein (LDL) cholesterol has been long associated with the risk for ischemic stroke, myocardial infarction, and cardiovascular death. For more than a decade, the main pharmacological option to ...

    • Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk 

      Milionis H., Barkas F., Ntaios G., Papavasileiou V., Vemmos K., Michel P., Elisaf M. (2016)
      Background/purpose A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors alirocumab and evolocumab. We aimed to investigate the ...

    • Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis 

      Sagris D., Ntaios G., Georgiopoulos G., Pateras K., Milionis H. (2021)
      [No abstract available]